Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors (REMIND)

Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment).

270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between.

Each patient will, therefore, receive two MRI during his/her participation in the study.

The two arms consist in :

• Dotarem® in the first MRI, then Gadovist®/Gadavist® in the second MRI.
• Gadovist®/Gadavist® in the first MRI, then Dotarem® in the second MRI.

Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.

MRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.

Study Overview

• Status: Completed
• Conditions: Primary Brain Tumor
• Intervention / Treatment: Drug: Dotarem®; Drug: Gadovist®/Gadavist®

• Study Type: Interventional
• Enrollment (Actual): 279
• Phase: Phase 4

Contacts and Locations

Study Locations

• Colombia
  • Bogota, Colombia
    • Fundacion ABOOD Shaio
  • Bogota, Colombia
    • Fundación CardioInfantil Instituto de Cardiología
  • Bogota, Colombia
    • Instituto Nacional de Cancerologia
  • Cali, Colombia
    • Centro Medico Imbanaco
  • Medellin, Colombia
    • Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM
  • Medellin, Colombia
    • Hospital Pablo Tobon Uribe
• Korea, Republic of
  • Suwon, Korea, Republic of
    • Ajou University Hospital
  • Chungcheongbuk-do
    • Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 361-711
      • Chungbuk National University
  • Jeollabuk-do
    • Jeonju-si, Jeollabuk-do, Korea, Republic of, 561-712
      • Chonbuk national Univ Hosp
  • Seocho-gu
    • Seoul, Seocho-gu, Korea, Republic of, 137-701
      • Seoul St.Mary Hospital
  • Songpa-Gu
    • Seoul, Songpa-Gu, Korea, Republic of, 138-736
      • Asan Medical Center
• Mexico
  • Chihuahua, Mexico, 31238
    • Hospital CIMA
  • Monterrey, Mexico
    • Centro Regiomontano de Investigacion S.C.
  • Tlanepantla, Mexico
    • Clinical Research Institute S.C.
  • Guanajuato
    • Leon, Guanajuato, Mexico, 37000
      • Morales Vargas Centro de Investigación S.C.
  • Mexico Distrito Federal
    • Mexico, Mexico Distrito Federal, Mexico, 5300
      • Centro Neurologico ABC
  • Nuevo Leon
    • Monterrey, Nuevo Leon, Mexico, 64020
      • Hospital Universitario Dr. Jose Eleuterio Gonzalez
  • Nuevo León
    • Monterrey, Nuevo León, Mexico
      • Winsett Rethman S.A. de C.V.
• United States
  • Alabama
    • Birmingham, Alabama, United States
      • University of Alabama at Birmingham
  • Arizona
    • Tucson, Arizona, United States, AZ 85724
      • University of Arizona Medical Center
  • California
    • Los Angeles, California, United States
      • Cedars-Sinai Medical Center
  • Connecticut
    • New Haven, Connecticut, United States
      • Yale University School Of Medicine
  • Florida
    • Hollywood, Florida, United States, FL 33021
      • Infinity Clinical Research, LLC
  • Michigan
    • Ann Arbor, Michigan, United States
      • University of Michigan Health System
    • Farmington Hills, Michigan, United States
      • Quest Research Institute
    • Grand Rapids, Michigan, United States
      • Spectrum Health
  • Missouri
    • St. Louis, Missouri, United States
      • Washington University
  • New York
    • Mineola, New York, United States, NY 11501
      • Winthrop University Hospital Clinical Trials Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States
      • Temple University Hospital
  • South Carolina
    • Charleston, South Carolina, United States
      • MUSC (Medical University of South Carolina)
  • Vermont
    • Burlington, Vermont, United States
      • UVM MRI Center for Biomedical Imaging
  • Washington
    • Seattle, Washington, United States
      • University of Washington Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Female or male adult patient (patient having reached legal majority age)
• Patient with known or highly suspected primary intracranial tumors (intra-axial or extra-axial) detected by previous CT or MRI examination who are scheduled to undergo a routine contrast-enhanced MRI
• Female patient must have effective contraception throughout the study and must have a negative urine pregnancy test at inclusion, or be surgically sterilized, or post-menopausal (minimum 12 months of amenorrhea)
• Patient having provided his/her written informed consent to participate in the trial prior to any study-related procedure being conducted
• Patient with national health insurance (according to local regulatory requirements)

Exclusion Criteria:

• Patient with rapidly evolving brain tumor that could change in appearance between the time of the two study MRI examinations.
• Patient undergoing current or recent treatment within past 6 weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy.
• Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe claustrophobia, infusion pumps, cochlear implants metallic or others according to the imaging site standard practice)
• Patient with known severely impaired renal function (defined as eGFR MDRD< 30 ml/min/1.73m2)
• Patient with known Class III/IV congestive heart failure according to the New York Heart Association classification
• Patient with known severe adverse drug reaction or contraindication to Gadolinium-Based Contrast Agent
• Patient having received any contrast agent within 48 hours prior to first study contrast agent injection scheduled for the study and patient expected to receive any other contrast agent within 24 hours of the last study contrast agent injection
• Patient presenting with any condition which, based on the investigator's clinical judgment, would prevent the patient from completing all trial assessments and visits
• Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial
• Pregnant or breast feeding female patient
• Patient already included in this trial
• Patient included in another clinical trial involving an IMP within 30 days before the first investigational contrast agent injection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dotarem®/Gadovist®; Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI	Drug: Dotarem®; Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.; Drug: Gadovist®/Gadavist®; Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Experimental: Gadovist®/Dotarem®; Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI	Drug: Dotarem®; Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.; Drug: Gadovist®/Gadavist®; Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent	Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale: 0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.	Up to 15 days after randomization

Collaborators and Investigators

• Sponsor: Guerbet
• Investigators: Study Chair: Kenneth Maravilla, MD, UNIVERSITY OF WASHINGTON MEDICAL CENTER, SEATTLE, USA

Study record dates

Study Major Dates

• Study Start: June 1, 2014
• Primary Completion (Actual): September 1, 2015
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: January 10, 2014
• First Submitted That Met QC Criteria: January 10, 2014
• First Posted (Estimate): January 13, 2014

Study Record Updates

• Last Update Posted (Estimate): December 30, 2016
• Last Update Submitted That Met QC Criteria: November 9, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Primary brain tumor
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms; Neoplasms by Site; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Neoplasms
• Other Study ID Numbers: DGD-44-058